Hans Prenen

33PUBLICATIONS

391CO-AUTHORS

Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer cell biologyCheminformatics and quantitative structure-activity relationships

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (33)

Sort by Publication Date:

|Jul 06, 2026

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.

|May 13, 2026

Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

|Apr 21, 2026

Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

|Mar 27, 2026

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Maria Vieito, Elisa Fontana, Catherine H Han

|Mar 04, 2026

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

Alison M Schram, John J Park, Antoine Italiano

|Dec 29, 2025

Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.

Shubham Pant, Joon Oh Park, Wu-Chou Su

Pageof 6

Frequent Collaborators

Nino Keshelava

Timon Vandamme

David Dejardin

Christophe Deben

Eva Segelov

Christof Vulsteke

Ruth Plummer

Jonas Van Audenaerde

Evelien Smits

Laure-Anne Teuwen

Frequent Collaborators

Nino Keshelava

Timon Vandamme

David Dejardin

Christophe Deben